A clinical co-founder. An AI product founder. An engineering lead. An operator. Specialist advisor pathway in motion. Enough to ship a clinical product responsibly without overbuilding.
Three of four founders have a parent or sibling with Type 2 diabetes, PCOS, or pre-diabetes. We have watched the same loop run in our own homes — the doctor's diagnosis, the printed diet chart, the gradual return to family meals, the worse lab result at the next visit, the medication escalation.
The clinical evidence for what should happen is settled. DiRECT showed 46% diabetes remission through structured dietary intervention. DASH-Sodium showed BP reduction comparable to first-line antihypertensives through diet alone. The literature is not the bottleneck. The bottleneck is what happens between Tuesday morning's prescription and Tuesday evening's dinner.
That is what AVOLA is being built to address.
AVOLA is not an MVP we plan to flip. We are building the household execution layer for preventive health in India — six conditions at launch, expanded based on cohort outcomes and clinical advisor input. We expect this to be a 10-year company. Investors and advisors who join at this stage are joining for the long arc.
Most healthtech founders are technologists who hire clinicians late. AVOLA was founded with a practising MD paediatrician as co-founder from Day 0 — clinical rigor in the DNA, not bolted on. Most clinical-nutrition founders are doctors who hire AI talent late. AVOLA was founded with a 15-year AI product person as CEO. The pairing is rare; the result is a clinical product that is also genuinely AI-native.
15+ years building production AI at Micron Technology and IBM — environments where reliability determines outcomes. Stanford (Launching Startup) · ISB (Product Management) · BE, MBA in Business Analytics. Built the UZ Brussels research conversation. Drives product, fundraising, and GTM.
MD Pediatrician with 15+ years pediatrics and ICU experience. MBBS, MD Pediatrics. American Academy Allergy & Asthma. PG Diploma + Fellowship in Pediatric Nutrition. Aster, CloudNine, Medicover, St. John's, KEM Mumbai. Clinical strategy and advisory anchor for AVOLA's six programs.
Founder of Streakify Technologies. BE Computer Science. Full-stack and mobile engineering. React Native · Node.js · FastAPI · ML pipeline experience. Owns engineering, architecture, and technical hiring for AVOLA.
MBA, MS Ramaiah University. Ex-IISc and Ex-Wipro. Finance, operations, and GTM execution. Co-built the UZ Brussels partnership conversation. Owns operations, finance, and partnerships for the company.
AVOLA's clinical scope spans six conditions across endocrinology, gynaecology, paediatrics, and cardiology. The founding clinical bench cannot cover all of these alone. We are engaging specialist advisors deliberately, condition by condition, to validate protocols before each program ships.
For T2D, pre-diabetes, and the metabolic markers across PCOS and adult-metabolic-weight programs. Phase 1 priority post-funding.
For PCOS and pre-conception programs. Required at protocol level, not just patient encounter level. Phase 1 priority.
Currently covered by the founding-team CMO. Additional paediatric advisor capacity added in Year 2 as paediatric program volume scales.
EpicureAI Labs Pvt. Ltd. registered with DPIIT (Department for Promotion of Industry and Internal Trade), Government of India.
Protocol Provenance v1.0 documents the 29 peer-reviewed studies underlying the six AVOLA programs, confidence-rated.
Pre-seed in progress. CCD/SAFE instrument, ₹16 Cr cap, 15–18 months runway. Targeting Seed round at end of cohort 1.
Dr. Elisabeth De Waele, Head of Clinical Nutrition at UZ Brussels, confirmed appetite for co-development of clinical modules with research studies attached — specifically for GDM and Type 2 diabetes nutrition protocols benchmarked across South Asian and European cohorts. The conversation continues on regular cadence.
The Innoviris Explore grant pathway is live, with €50K–€150K non-dilutive support at 40–60% project funding ratio. Decision expected by Q4 2026 if AVOLA's pre-seed close enables the matching contribution.
An Indian clinical-nutrition product validated alongside a European university hospital research institution is not just credibility-building — it is structural. South Asian phenotype data is largely absent from European cardiometabolic research. Bringing Indian patient cohorts into peer-reviewed European studies, while adapting the resulting protocols back into Indian families' kitchens, is the kind of bidirectional collaboration that justifies institutional support beyond commercial returns alone.
Note: nothing in the Brussels conversation is signed. We treat it as a developing relationship, not a closed partnership.
AVOLA's pitch deck, thesis & analysis document, protocol provenance, and clinical evidence summary are available on request for serious investor and advisor conversations. We are looking for capital partners who can engage on a 10-year arc — not a 6-month sprint.